A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen.
James R. Berenson
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Research Funding - Onyx
Ori Yellin
No relevant relationships to disclose
Robert Dichmann
No relevant relationships to disclose
Dipti Patel-Donnelly
No relevant relationships to disclose
Ralph V. Boccia
No relevant relationships to disclose
James D. Hilger
No relevant relationships to disclose
Youram Nassir
No relevant relationships to disclose
Regina A. Swift
No relevant relationships to disclose
Robert A. Vescio
No relevant relationships to disclose